Reperfusion‐induced myocardial dysfunction is prevented by endogenous annexin‐A1 and its N‐terminal‐derived peptide Ac‐ANX‐A12‐26
- 18 December 2012
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 168 (1) , 238-252
Abstract
BACKGROUND AND PURPOSE: Annexin‐A1 (ANX‐A1) is an endogenous, glucocorticoid‐regulated anti‐inflammatory protein. The N‐terminal‐derived peptide Ac‐ANX‐A12–26 preserves cardiomyocyte viability, but the impact of ANX‐A1‐peptides on cardiac contractility is unknown. We now test the hypothesis that ANX‐A1 preserves post‐ischaemic recovery of left ventricular (LV) function.EXPERIMENTAL APPROACH: Ac‐ANX‐A12–26 was administered on reperfusion, to adult rat cardiomyocytes as well as hearts isolated from rats, wild‐type mice and mice deficient in endogenous ANX‐A1 (ANX‐A1–/–). Myocardial viability and recovery of LV function were determined.KEY RESULTS: Ischaemia–reperfusion markedly impaired both cardiomyocyte viability and recovery of LV function by 60%. Treatment with exogenous Ac‐ANX‐A12–26 at the onset of reperfusion prevented cardiomyocyte injury and significantly improved recovery of LV function, in both intact rat and wild‐type mouse hearts. Ac‐ANX‐A12–26 cardioprotection was abolished by either formyl peptide receptor (FPR)‐nonselective or FPR1‐selective antagonists, Boc2 and cyclosporin H, but was relatively insensitive to the FPR2‐selective antagonist QuinC7. ANX‐A1‐induced cardioprotection was associated with increased phosphorylation of the cell survival kinase Akt. ANX‐A1−/− exaggerated impairment of post‐ischaemic recovery of LV function, in addition to selective LV FPR1 down‐regulation.CONCLUSIONS AND IMPLICATIONS: These data represent the first evidence that ANX‐A1 affects myocardial function. Our findings suggest ANX‐A1 is an endogenous regulator of post‐ischaemic recovery of LV function. Furthermore, the ANX‐A1‐derived peptide Ac‐ANX‐A12–26 on reperfusion rescues LV function, probably via activation of FPR1. ANX‐A1‐based therapies may thus represent a novel clinical approach for the prevention and treatment of myocardial reperfusion injury.Keywords
This publication has 41 references indexed in Scilit:
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- FPR2/ALX receptor expression and internalization are critical for lipoxin A 4 and annexin‐derived peptide‐stimulated phagocytosisThe FASEB Journal, 2010
- Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agentsBioorganic & Medicinal Chemistry Letters, 2006
- Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvementBlood, 2006
- Sodium Nitroprusside Protects Adult Rat Cardiac Myocytes From Cellular Injury Induced by Simulated IschemiaJournal of Cardiovascular Pharmacology, 2006
- Annexin‐1 peptide Anx‐12–26 protects adult rat cardiac myocytes from cellular injury induced by simulated ischaemiaBritish Journal of Pharmacology, 2005
- Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological processInternational Journal of Cardiology, 2005
- Postconditioning A new link in nature’s armor against myocardial ischemia–reperfusion injuryBasic Research in Cardiology, 2005
- Formyl‐peptide receptor is not involved in the protection afforded by annexin 1 in murine acute myocardial infarctThe FASEB Journal, 2004